title: Porcine embryonic brain cell cytotoxicity mediated by human natural killer cells.
abstract: Intracerebral transplantation of porcine embryonic dopamine-producing neurons has been suggested as a method to treat patients with Parkinson's disease. Even though the brain is an immunologically privileged site, neuronal xenografts are usually rejected within a few weeks. T cells are important for this process, but the exact cellular events leading to rejection are poorly characterized. Brain cells from ventral mesencephalon of 26-27-day-old pig embryos were used as target cells in flow cytometry-assessed cytotoxicity assays using non- and IL-2-activated CD3- CD16+ CD56+ human natural killer (NK) cells as effector cells. The ability of human NK cells to kill pig embryonic brain cells by antibody-dependent cellular cytotoxicity (ADCC) in the presence of nondepleted and anti-Gal alpha1,3Gal antibody-depleted human blood group AB serum (AB serum) was evaluated using the same assay. Both nondepleted and anti-Gal alpha1,3Gal antibody-depleted AB serum could mediate ADCC of pig embryonic VM cells when human NK cells were used as effector cells. Nonactivated NK cells did not show any direct cytotoxic effect on freshly isolated VM cells, whereas IL-2-activated NK cells killed approximately 50% of the VM cells at an effector-to-target ratio of 50:1 in a 4-h cytotoxicity assay. Activation of VM cells by TNF-alpha did not change their sensitivity to human NK cell cytotoxicity. Human NK cells may thus contribute to a cellular rejection of pig neuronal xenografts by ADCC, or following IL-2 activation, by a direct cytotoxic effect.
authors.affiliation: Division of Clinical Immunology, Karolinska Institutet, Huddinge University Hospital, Sweden.
authors.forename: S
authors.initials: S
authors.lastname: Sumitran
authors.forename: P
authors.initials: P
authors.lastname: Anderson
authors.forename: H
authors.initials: H
authors.lastname: Widner
authors.forename: J
authors.initials: J
authors.lastname: Holgersson
mesh_terms: D000017:ABO Blood-Group System / Q000276:immunology; D000818:Animals; D000920:Antibody-Dependent Cell Cytotoxicity; D001921:Brain / Q000166:cytology* / Q000196:embryology / Q000276:immunology*; D016380:Brain Tissue Transplantation / Q000276:immunology; D003602:Cytotoxicity, Immunologic; D004622:Embryo, Mammalian / Q000166:cytology / Q000276:immunology; D016332:Fetal Tissue Transplantation / Q000276:immunology; D015395:Histocompatibility Antigens Class I / Q000276:immunology; D006801:Humans; D066298:In Vitro Techniques; D007376:Interleukin-2 / Q000494:pharmacology; D007694:Killer Cells, Natural / Q000276:immunology*; D008636:Mesencephalon / Q000166:cytology / Q000276:immunology; D009474:Neurons / Q000276:immunology / Q000637:transplantation; D010300:Parkinson Disease / Q000601:surgery; D013552:Swine; D014183:Transplantation, Heterologous; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology
chemical_list: D000017:ABO Blood-Group System; D015395:Histocompatibility Antigens Class I; D007376:Interleukin-2; D014409:Tumor Necrosis Factor-alpha